| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| VRTX - Vertex Pharmaceuticals Inc | BUY | 1,760 @ USD 419.89 | USD 739,006 | The ETF bought 1760 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 419.89 compared to the previous average buy price of 440.464. This is -4.7% lower than average price of previous purchases of VRTX. |
| GILD - Guild Esports Plc | BUY | 6,090 @ USD 118.44 | USD 721,300 | The ETF bought 6090 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 118.44 compared to the previous average buy price of 111.578. This is 6.1% higher than average price of previous purchases of GILD. |
| AMGN - Amgen Inc | BUY | 2,390 @ USD 292 | USD 697,880 | The ETF bought 2390 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 292 compared to the previous average buy price of 287.776. This is 1.5% higher than average price of previous purchases of AMGN. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 860 @ USD 654.04 | USD 562,474 | The ETF bought 860 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 654.04 compared to the previous average buy price of 626.655. This is 4.4% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 1,080 @ USD 449.56 | USD 485,525 | The ETF bought 1080 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 449.56 compared to the previous average buy price of 351.855. This is 27.8% higher than average price of previous purchases of ALNY. |
| AZN - AstraZeneca PLC | BUY | 4,305 @ USD 82.34 | USD 354,474 | The ETF bought 4305 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 82.34 compared to the previous average buy price of 74.0636. This is 11.2% higher than average price of previous purchases of AZN. |
| INSM - Insmed Inc | BUY | 1,755 @ USD 194.22 | USD 340,856 | The ETF bought 1755 new shares of INSM (Insmed Inc). The shares were bought for an average price of 194.22 compared to the previous average buy price of 109.72. This is 77.0% higher than average price of previous purchases of INSM. |
| ARGX - argenx NV ADR | BUY | 255 @ USD 820.36 | USD 209,192 | The ETF bought 255 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 820.36 compared to the previous average buy price of 624.94. This is 31.3% higher than average price of previous purchases of ARGX. |
| BIIB - Biogen Inc | BUY | 1,220 @ USD 149.61 | USD 182,524 | The ETF bought 1220 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 149.61 compared to the previous average buy price of 137.298. This is 9.0% higher than average price of previous purchases of BIIB. |
| UTHR - United Therapeutics Corporation | BUY | 375 @ USD 453.53 | USD 170,074 | The ETF bought 375 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 453.53 compared to the previous average buy price of 336.675. This is 34.7% higher than average price of previous purchases of UTHR. |
| INCY - Incyte Corporation | BUY | 1,625 @ USD 92.59 | USD 150,459 | The ETF bought 1625 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 92.59 compared to the previous average buy price of 72.126. This is 28.4% higher than average price of previous purchases of INCY. |
| MEDP - Medpace Holdings Inc | BUY | 235 @ USD 580.37 | USD 136,387 | The ETF bought 235 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 580.37 compared to the previous average buy price of 377.628. This is 53.7% higher than average price of previous purchases of MEDP. |
| RPRX - Royalty Pharma Plc | BUY | 3,585 @ USD 36.94 | USD 132,430 | The ETF bought 3585 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 36.94 compared to the previous average buy price of 35.3022. This is 4.6% higher than average price of previous purchases of RPRX. |
| ILMN - Illumina Inc | BUY | 1,275 @ USD 99.01 | USD 126,238 | The ETF bought 1275 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 99.01 compared to the previous average buy price of 95.9216. This is 3.2% higher than average price of previous purchases of ILMN. |
| SMMT - Summit Therapeutics PLC | BUY | 6,185 @ USD 18.64 | USD 115,288 | The ETF bought 6185 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 18.64 compared to the previous average buy price of 21.4993. This is -13.3% lower than average price of previous purchases of SMMT. |
| NBIX - Neurocrine Biosciences Inc | BUY | 825 @ USD 138.04 | USD 113,883 | The ETF bought 825 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 138.04 compared to the previous average buy price of 128.631. This is 7.3% higher than average price of previous purchases of NBIX. |
| SNY - Sanofi ADR | BUY | 2,235 @ USD 50.94 | USD 113,851 | The ETF bought 2235 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 50.94 compared to the previous average buy price of 49.9793. This is 1.9% higher than average price of previous purchases of SNY. |
| ROIV - Roivant Sciences Ltd | BUY | 5,665 @ USD 19.58 | USD 110,921 | The ETF bought 5665 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 19.58 compared to the previous average buy price of 12.3508. This is 58.5% higher than average price of previous purchases of ROIV. |
| ASND - Ascendis Pharma AS | BUY | 505 @ USD 203.71 | USD 102,874 | The ETF bought 505 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 203.71 compared to the previous average buy price of 176.103. This is 15.7% higher than average price of previous purchases of ASND. |
| BBIO - BridgeBio Pharma Inc | BUY | 1,595 @ USD 63.37 | USD 101,075 | The ETF bought 1595 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 63.37 compared to the previous average buy price of 43.2649. This is 46.5% higher than average price of previous purchases of BBIO. |
| VTRS - Viatris Inc | BUY | 9,715 @ USD 10.36 | USD 100,647 | The ETF bought 9715 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 10.36 compared to the previous average buy price of 9.53015. This is 8.7% higher than average price of previous purchases of VTRS. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 1,330 @ USD 74.17 | USD 98,646 | The ETF bought 1330 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 74.17 compared to the previous average buy price of 46.4572. This is 59.7% higher than average price of previous purchases of IONS. |
| RVMD - Revolution Medicines Inc | BUY | 1,560 @ USD 58.87 | USD 91,837 | The ETF bought 1560 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 58.87 compared to the previous average buy price of 40.3351. This is 46.0% higher than average price of previous purchases of RVMD. |
| MRNA - Moderna Inc | BUY | 3,230 @ USD 28.14 | USD 90,892 | The ETF bought 3230 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 28.14 compared to the previous average buy price of 29.2619. This is -3.8% lower than average price of previous purchases of MRNA. |
| BNTX - BioNTech SE | BUY | 835 @ USD 104.67 | USD 87,399 | The ETF bought 835 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 104.67 compared to the previous average buy price of 105.088. This is -0.4% lower than average price of previous purchases of BNTX. |
| EXEL - Exelixis Inc | BUY | 2,235 @ USD 38.94 | USD 87,031 | The ETF bought 2235 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 38.94 compared to the previous average buy price of 41.038. This is -5.1% lower than average price of previous purchases of EXEL. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 1,590 @ USD 51.91 | USD 82,537 | The ETF bought 1590 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 51.91 compared to the previous average buy price of 58.6046. This is -11.4% lower than average price of previous purchases of BMRN. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 185 @ USD 427.52 | USD 79,091 | The ETF bought 185 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 427.52 compared to the previous average buy price of 340.127. This is 25.7% higher than average price of previous purchases of MDGL. |
| RNA - Avidity Biosciences Inc | BUY | 1,065 @ USD 69.69 | USD 74,220 | The ETF bought 1065 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 69.69 compared to the previous average buy price of 34.4002. This is 102.6% higher than average price of previous purchases of RNA. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 505 @ USD 136.3 | USD 68,832 | The ETF bought 505 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 136.3 compared to the previous average buy price of 120.829. This is 12.8% higher than average price of previous purchases of JAZZ. |
| HALO - Halozyme Therapeutics Inc | BUY | 970 @ USD 64.63 | USD 62,691 | The ETF bought 970 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 64.63 compared to the previous average buy price of 59.2651. This is 9.1% higher than average price of previous purchases of HALO. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 555 @ USD 111.81 | USD 62,055 | The ETF bought 555 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 111.81 compared to the previous average buy price of 73.5183. This is 52.1% higher than average price of previous purchases of RYTM. |
| CYTK - Cytokinetics Inc | BUY | 990 @ USD 62.25 | USD 61,628 | The ETF bought 990 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 62.25 compared to the previous average buy price of 41.5047. This is 50.0% higher than average price of previous purchases of CYTK. |
| MRUS - Merus BV | BUY | 630 @ USD 95.06 | USD 59,888 | The ETF bought 630 new shares of MRUS (Merus BV). The shares were bought for an average price of 95.06 compared to the previous average buy price of 61.3182. This is 55.0% higher than average price of previous purchases of MRUS. |
| AXSM - Axsome Therapeutics Inc | BUY | 415 @ USD 133.15 | USD 55,257 | The ETF bought 415 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 133.15 compared to the previous average buy price of 113.448. This is 17.4% higher than average price of previous purchases of AXSM. |
| NUVL - Nuvalent Inc | BUY | 555 @ USD 98.17 | USD 54,484 | The ETF bought 555 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 98.17 compared to the previous average buy price of 81.025. This is 21.2% higher than average price of previous purchases of NUVL. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 1,150 @ USD 42.31 | USD 48,657 | The ETF bought 1150 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 42.31 compared to the previous average buy price of 20.1007. This is 110.5% higher than average price of previous purchases of ARWR. |
| PCVX - Vaxcyte Inc | BUY | 1,080 @ USD 44.75 | USD 48,330 | The ETF bought 1080 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 44.75 compared to the previous average buy price of 44.7686. This is 0.0% lower than average price of previous purchases of PCVX. |
| CRSP - Crispr Therapeutics AG | BUY | 755 @ USD 61.1 | USD 46,131 | The ETF bought 755 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 61.1 compared to the previous average buy price of 51.9687. This is 17.6% higher than average price of previous purchases of CRSP. |
| KRYS - Krystal Biotech Inc | BUY | 240 @ USD 189.08 | USD 45,379 | The ETF bought 240 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 189.08 compared to the previous average buy price of 158.305. This is 19.4% higher than average price of previous purchases of KRYS. |
| PTCT - PTC Therapeutics Inc | BUY | 660 @ USD 68.11 | USD 44,953 | The ETF bought 660 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 68.11 compared to the previous average buy price of 53.863. This is 26.5% higher than average price of previous purchases of PTCT. |
| ALKS - Alkermes Plc | BUY | 1,375 @ USD 30.82 | USD 42,378 | The ETF bought 1375 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 30.82 compared to the previous average buy price of 30.399. This is 1.4% higher than average price of previous purchases of ALKS. |
| PTGX - Protagonist Therapeutics Inc | BUY | 520 @ USD 77.85 | USD 40,482 | The ETF bought 520 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 77.85 compared to the previous average buy price of 55.034. This is 41.5% higher than average price of previous purchases of PTGX. |
| ACLX - Arcellx Inc | BUY | 460 @ USD 87.5 | USD 40,250 | The ETF bought 460 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 87.5 compared to the previous average buy price of 70.9475. This is 23.3% higher than average price of previous purchases of ACLX. |
| KYMR - Kymera Therapeutics Inc | BUY | 595 @ USD 61.44 | USD 36,557 | The ETF bought 595 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 61.44 compared to the previous average buy price of 44.9352. This is 36.7% higher than average price of previous purchases of KYMR. |
| IMVT - Immunovant Inc | BUY | 1,465 @ USD 24.82 | USD 36,361 | The ETF bought 1465 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 24.82 compared to the previous average buy price of 17.6703. This is 40.5% higher than average price of previous purchases of IMVT. |
| AKRO - Akero Therapeutics Inc | BUY | 665 @ USD 54.26 | USD 36,083 | The ETF bought 665 new shares of AKRO (Akero Therapeutics Inc). The shares were bought for an average price of 54.26 compared to the previous average buy price of 49.0206. This is 10.7% higher than average price of previous purchases of AKRO. |
| PRAX - Praxis Precision Medicines Inc | BUY | 175 @ USD 201 | USD 35,175 | The ETF bought 175 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 201 compared to the previous average buy price of 54.3512. This is 269.8% higher than average price of previous purchases of PRAX. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 785 @ USD 43.28 | USD 33,975 | The ETF bought 785 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 43.28 compared to the previous average buy price of 34.5429. This is 25.3% higher than average price of previous purchases of CRNX. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 1,415 @ USD 22.74 | USD 32,177 | The ETF bought 1415 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 22.74 compared to the previous average buy price of 20.7015. This is 9.8% higher than average price of previous purchases of ACAD. |
| QURE - Uniqure NV | BUY | 455 @ USD 67.86 | USD 30,876 | The ETF bought 455 new shares of QURE (Uniqure NV). The shares were bought for an average price of 67.86 compared to the previous average buy price of 21.7435. This is 212.1% higher than average price of previous purchases of QURE. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 165 @ USD 187.06 | USD 30,865 | The ETF bought 165 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 187.06 compared to the previous average buy price of 128.962. This is 45.1% higher than average price of previous purchases of LGND. |
| ADMA - ADMA Biologics Inc | BUY | 2,000 @ USD 15.27 | USD 30,540 | The ETF bought 2000 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 15.27 compared to the previous average buy price of 17.5099. This is -12.8% lower than average price of previous purchases of ADMA. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 420 @ USD 72.2 | USD 30,324 | The ETF bought 420 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 72.2 compared to the previous average buy price of 54.458. This is 32.6% higher than average price of previous purchases of MIRM. |
| RARE - Ultragenyx | BUY | 810 @ USD 35.17 | USD 28,488 | The ETF bought 810 new shares of RARE (Ultragenyx). The shares were bought for an average price of 35.17 compared to the previous average buy price of 36.6728. This is -4.1% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 810 @ USD 35.17 | USD 28,488 | The ETF bought 810 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 35.17 compared to the previous average buy price of 36.6728. This is -4.1% lower than average price of previous purchases of RARE. |
| DYN - Dyne Therapeutics Inc | BUY | 1,190 @ USD 23.55 | USD 28,025 | The ETF bought 1190 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 23.55 compared to the previous average buy price of 12.2202. This is 92.7% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 1,190 @ USD 23.55 | USD 28,025 | The ETF bought 1190 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 23.55 compared to the previous average buy price of 12.2202. This is 92.7% higher than average price of previous purchases of DYN. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 645 @ USD 42.67 | USD 27,522 | The ETF bought 645 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 42.67 compared to the previous average buy price of 35.2693. This is 21.0% higher than average price of previous purchases of XENE. |
| GRAL - GRAIL, LLC | BUY | 300 @ USD 91.15 | USD 27,345 | The ETF bought 300 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 91.15 compared to the previous average buy price of 50.5761. This is 80.2% higher than average price of previous purchases of GRAL. |
| CGON - CG Oncology, Inc. Common stock | BUY | 640 @ USD 42.47 | USD 27,181 | The ETF bought 640 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 42.47 compared to the previous average buy price of 29.3291. This is 44.8% higher than average price of previous purchases of CGON. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 470 @ USD 56.5 | USD 26,555 | The ETF bought 470 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 56.5 compared to the previous average buy price of 36.6206. This is 54.3% higher than average price of previous purchases of SUPN. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 2,635 @ USD 10 | USD 26,350 | The ETF bought 2635 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 10 compared to the previous average buy price of 8.67688. This is 15.2% higher than average price of previous purchases of AMRX. |
| IRON - Ironveld Plc | BUY | 290 @ USD 85.75 | USD 24,868 | The ETF bought 290 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 85.75 compared to the previous average buy price of 57.3732. This is 49.5% higher than average price of previous purchases of IRON. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 990 @ USD 24.92 | USD 24,671 | The ETF bought 990 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 24.92 compared to the previous average buy price of 15.6565. This is 59.2% higher than average price of previous purchases of ARQT. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 355 @ USD 68.96 | USD 24,481 | The ETF bought 355 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 68.96 compared to the previous average buy price of 47.8658. This is 44.1% higher than average price of previous purchases of TARS. |
| SRRK - Scholar Rock Holding Corp | BUY | 805 @ USD 29.37 | USD 23,643 | The ETF bought 805 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 29.37 compared to the previous average buy price of 35.2176. This is -16.6% lower than average price of previous purchases of SRRK. |
| VCYT - Veracyte Inc | BUY | 660 @ USD 35.33 | USD 23,318 | The ETF bought 660 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 35.33 compared to the previous average buy price of 30.8933. This is 14.4% higher than average price of previous purchases of VCYT. |
| IDYA - Ideaya Biosciences Inc | BUY | 735 @ USD 31.6 | USD 23,226 | The ETF bought 735 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 31.6 compared to the previous average buy price of 22.768. This is 38.8% higher than average price of previous purchases of IDYA. |
| FOLD - Amicus Therapeutics Inc | BUY | 2,545 @ USD 8.9 | USD 22,651 | The ETF bought 2545 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 8.9 compared to the previous average buy price of 7.2634. This is 22.5% higher than average price of previous purchases of FOLD. |
| LEGN - Legend Biotech Corp | BUY | 700 @ USD 32.25 | USD 22,575 | The ETF bought 700 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 32.25 compared to the previous average buy price of 34.8123. This is -7.4% lower than average price of previous purchases of LEGN. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 545 @ USD 41.12 | USD 22,410 | The ETF bought 545 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 41.12 compared to the previous average buy price of 18.6895. This is 120.0% higher than average price of previous purchases of MLYS. |
| TVTX - Travere Therapeutics Inc | BUY | 735 @ USD 29.65 | USD 21,793 | The ETF bought 735 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 29.65 compared to the previous average buy price of 19.0308. This is 55.8% higher than average price of previous purchases of TVTX. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 380 @ USD 56.04 | USD 21,295 | The ETF bought 380 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 56.04 compared to the previous average buy price of 42.9361. This is 30.5% higher than average price of previous purchases of APGE. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 1,255 @ USD 16.91 | USD 21,222 | The ETF bought 1255 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 16.91 compared to the previous average buy price of 11.6123. This is 45.6% higher than average price of previous purchases of ADPT. |
| AGIO - Agios Pharm | BUY | 480 @ USD 43.18 | USD 20,726 | The ETF bought 480 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 43.18 compared to the previous average buy price of 35.4416. This is 21.8% higher than average price of previous purchases of AGIO. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 3,595 @ USD 5.65 | USD 20,312 | The ETF bought 3595 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 5.65 compared to the previous average buy price of 5.8125. This is -2.8% lower than average price of previous purchases of RXRX. |
| BEAM - Beam Therapeutics Inc | BUY | 835 @ USD 23.8 | USD 19,873 | The ETF bought 835 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 23.8 compared to the previous average buy price of 20.4444. This is 16.4% higher than average price of previous purchases of BEAM. |
| DNLI - Denali Therapeutics Inc | BUY | 1,205 @ USD 16.38 | USD 19,738 | The ETF bought 1205 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 16.38 compared to the previous average buy price of 15.091. This is 8.5% higher than average price of previous purchases of DNLI. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 790 @ USD 24.33 | USD 19,221 | The ETF bought 790 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 24.33 compared to the previous average buy price of 16.0632. This is 51.5% higher than average price of previous purchases of CNTA. |
| COGT - Cogent Biosciences Inc | BUY | 1,155 @ USD 16.21 | USD 18,723 | The ETF bought 1155 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 16.21 compared to the previous average buy price of 9.40874. This is 72.3% higher than average price of previous purchases of COGT. |
| SRPT - Sarepta Therapeutics Inc | BUY | 805 @ USD 23.25 | USD 18,716 | The ETF bought 805 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 23.25 compared to the previous average buy price of 35.2786. This is -34.1% lower than average price of previous purchases of SRPT. |
| IBRX - Immunitybio Inc | BUY | 7,930 @ USD 2.36 | USD 18,715 | The ETF bought 7930 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.36 compared to the previous average buy price of 2.78938. This is -15.4% lower than average price of previous purchases of IBRX. |
| OCUL - Ocular Therapeutix Inc | BUY | 1,440 @ USD 11.82 | USD 17,021 | The ETF bought 1440 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 11.82 compared to the previous average buy price of 9.50156. This is 24.4% higher than average price of previous purchases of OCUL. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 180 @ USD 91.93 | USD 16,547 | The ETF bought 180 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 91.93 compared to the previous average buy price of 71.4541. This is 28.7% higher than average price of previous purchases of ANIP. |
| EWTX - Edgewise Therapeutics Inc | BUY | 870 @ USD 18.67 | USD 16,243 | The ETF bought 870 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 18.67 compared to the previous average buy price of 15.7242. This is 18.7% higher than average price of previous purchases of EWTX. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 490 @ USD 32.22 | USD 15,788 | The ETF bought 490 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 32.22 compared to the previous average buy price of 22.4581. This is 43.5% higher than average price of previous purchases of GPCR. |
| TWST - Twist Bioscience Corp | BUY | 500 @ USD 31.17 | USD 15,585 | The ETF bought 500 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 31.17 compared to the previous average buy price of 36.6898. This is -15.0% lower than average price of previous purchases of TWST. |
| VERA - Vera Therapeutics Inc | BUY | 525 @ USD 29.67 | USD 15,577 | The ETF bought 525 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 29.67 compared to the previous average buy price of 26.854. This is 10.5% higher than average price of previous purchases of VERA. |
| AVDL - Avadel Pharmaceuticals PLC | BUY | 805 @ USD 18.83 | USD 15,158 | The ETF bought 805 new shares of AVDL (Avadel Pharmaceuticals PLC). The shares were bought for an average price of 18.83 compared to the previous average buy price of 10.3868. This is 81.3% higher than average price of previous purchases of AVDL. |
| STOK - Stoke Therapeutics Inc | BUY | 460 @ USD 31.7 | USD 14,582 | The ETF bought 460 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 31.7 compared to the previous average buy price of 15.0138. This is 111.1% higher than average price of previous purchases of STOK. |
| VCEL - Vericel Corp Ord | BUY | 415 @ USD 34.53 | USD 14,330 | The ETF bought 415 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 34.53 compared to the previous average buy price of 41.0969. This is -16.0% lower than average price of previous purchases of VCEL. |
| MNKD - MannKind Corp | BUY | 2,545 @ USD 5.55 | USD 14,125 | The ETF bought 2545 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.55 compared to the previous average buy price of 4.7062. This is 17.9% higher than average price of previous purchases of MNKD. |
| JANX - Janux Therapeutics Inc | BUY | 495 @ USD 28.51 | USD 14,112 | The ETF bought 495 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 28.51 compared to the previous average buy price of 27.693. This is 3.0% higher than average price of previous purchases of JANX. |
| HRMY - Harmony Biosciences Holdings | BUY | 475 @ USD 28.9 | USD 13,728 | The ETF bought 475 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 28.9 compared to the previous average buy price of 31.8427. This is -9.2% lower than average price of previous purchases of HRMY. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 365 @ USD 37.29 | USD 13,611 | The ETF bought 365 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 37.29 compared to the previous average buy price of 29.1838. This is 27.8% higher than average price of previous purchases of KNSA. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 1,380 @ USD 9.71 | USD 13,400 | The ETF bought 1380 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 9.71 compared to the previous average buy price of 5.9209. This is 64.0% higher than average price of previous purchases of XERS. |
| ABCL - Abcellera Biologics Inc | BUY | 2,475 @ USD 5.36 | USD 13,266 | The ETF bought 2475 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 5.36 compared to the previous average buy price of 3.85222. This is 39.1% higher than average price of previous purchases of ABCL. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 1,090 @ USD 12.12 | USD 13,211 | The ETF bought 1090 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 12.12 compared to the previous average buy price of 8.84453. This is 37.0% higher than average price of previous purchases of AUPH. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 1,740 @ USD 7.25 | USD 12,615 | The ETF bought 1740 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.25 compared to the previous average buy price of 8.38815. This is -13.6% lower than average price of previous purchases of BCRX. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 640 @ USD 19.12 | USD 12,237 | The ETF bought 640 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 19.12 compared to the previous average buy price of 14.0273. This is 36.3% higher than average price of previous purchases of ZYME. |
| SYRE - Spyre Therapeutics Inc. | BUY | 495 @ USD 24.26 | USD 12,009 | The ETF bought 495 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 24.26 compared to the previous average buy price of 17.1044. This is 41.8% higher than average price of previous purchases of SYRE. |
| TXG - 10X Genomics Inc | BUY | 960 @ USD 12.44 | USD 11,942 | The ETF bought 960 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 12.44 compared to the previous average buy price of 11.9603. This is 4.0% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 960 @ USD 12.44 | USD 11,942 | The ETF bought 960 new shares of TXG (Terex Corporation). The shares were bought for an average price of 12.44 compared to the previous average buy price of 11.9603. This is 4.0% higher than average price of previous purchases of TXG. |
| NVCR - Novocure Ltd | BUY | 925 @ USD 12.82 | USD 11,859 | The ETF bought 925 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 12.82 compared to the previous average buy price of 17.1081. This is -25.1% lower than average price of previous purchases of NVCR. |
| ELVN - Enliven Therapeutics Inc. | BUY | 490 @ USD 23.97 | USD 11,745 | The ETF bought 490 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 23.97 compared to the previous average buy price of 20.7384. This is 15.6% higher than average price of previous purchases of ELVN. |
| HROW - Harrow Health Inc | BUY | 305 @ USD 37.56 | USD 11,456 | The ETF bought 305 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 37.56 compared to the previous average buy price of 33.1002. This is 13.5% higher than average price of previous purchases of HROW. |
| NVAX - Novavax Inc | BUY | 1,350 @ USD 8.43 | USD 11,381 | The ETF bought 1350 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 8.43 compared to the previous average buy price of 7.37331. This is 14.3% higher than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 1,350 @ USD 8.43 | USD 11,381 | The ETF bought 1350 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 8.43 compared to the previous average buy price of 7.37331. This is 14.3% higher than average price of previous purchases of NVAX. |
| WVE - Wave Life Sciences Ltd | BUY | 1,355 @ USD 8.3 | USD 11,247 | The ETF bought 1355 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 8.3 compared to the previous average buy price of 8.48103. This is -2.1% lower than average price of previous purchases of WVE. |
| TSHA - Taysha Gene Therapies Inc | BUY | 2,265 @ USD 4.91 | USD 11,121 | The ETF bought 2265 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.91 compared to the previous average buy price of 2.79028. This is 76.0% higher than average price of previous purchases of TSHA. |
| NTLA - Intellia Therapeutics Inc | BUY | 900 @ USD 12.265 | USD 11,039 | The ETF bought 900 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 12.265 compared to the previous average buy price of 12.5213. This is -2.0% lower than average price of previous purchases of NTLA. |
| IMCR - Immunocore Holdings Ltd | BUY | 340 @ USD 32.19 | USD 10,945 | The ETF bought 340 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 32.19 compared to the previous average buy price of 32.6459. This is -1.4% lower than average price of previous purchases of IMCR. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 805 @ USD 13.34 | USD 10,739 | The ETF bought 805 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 13.34 compared to the previous average buy price of 10.3146. This is 29.3% higher than average price of previous purchases of ORIC. |
| SANA - Sana Biotechnology Inc | BUY | 2,180 @ USD 4.9 | USD 10,682 | The ETF bought 2180 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 4.9 compared to the previous average buy price of 3.07256. This is 59.5% higher than average price of previous purchases of SANA. |
| RLAY - Relay Therapeutics Inc | BUY | 1,435 @ USD 7.34 | USD 10,533 | The ETF bought 1435 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 7.34 compared to the previous average buy price of 4.01674. This is 82.7% higher than average price of previous purchases of RLAY. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 740 @ USD 14.05 | USD 10,397 | The ETF bought 740 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 14.05 compared to the previous average buy price of 6.63062. This is 111.9% higher than average price of previous purchases of AMLX. |
| PGEN - Precigen Inc | BUY | 2,535 @ USD 4.05 | USD 10,267 | The ETF bought 2535 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.05 compared to the previous average buy price of 2.15634. This is 87.8% higher than average price of previous purchases of PGEN. |
| DVAX - Dynavax Technologies Corporation | BUY | 975 @ USD 10.4 | USD 10,140 | The ETF bought 975 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 10.4 compared to the previous average buy price of 10.4213. This is -0.2% lower than average price of previous purchases of DVAX. |
| ZLAB - Zai Lab Ltd | BUY | 395 @ USD 25.52 | USD 10,080 | The ETF bought 395 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 25.52 compared to the previous average buy price of 34.4107. This is -25.8% lower than average price of previous purchases of ZLAB. |
| ARDX - Ardelyx Inc | BUY | 2,005 @ USD 5.01 | USD 10,045 | The ETF bought 2005 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 5.01 compared to the previous average buy price of 4.56725. This is 9.7% higher than average price of previous purchases of ARDX. |
| CVAC - CureVac NV | BUY | 1,870 @ USD 5.36 | USD 10,023 | The ETF bought 1870 new shares of CVAC (CureVac NV). The shares were bought for an average price of 5.36 compared to the previous average buy price of 4.78951. This is 11.9% higher than average price of previous purchases of CVAC. |
| GMAB - Genmab AS | BUY | 345 @ USD 28.67 | USD 9,891 | The ETF bought 345 new shares of GMAB (Genmab AS). The shares were bought for an average price of 28.67 compared to the previous average buy price of 23.0566. This is 24.3% higher than average price of previous purchases of GMAB. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 715 @ USD 13.39 | USD 9,574 | The ETF bought 715 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 13.39 compared to the previous average buy price of 11.4896. This is 16.5% higher than average price of previous purchases of SNDX. |
| AMPH - Amphastar P | BUY | 385 @ USD 24.66 | USD 9,494 | The ETF bought 385 new shares of AMPH (Amphastar P). The shares were bought for an average price of 24.66 compared to the previous average buy price of 25.6253. This is -3.8% lower than average price of previous purchases of AMPH. |
| INVA - Innoviva Inc | BUY | 520 @ USD 17.95 | USD 9,334 | The ETF bought 520 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 17.95 compared to the previous average buy price of 18.9009. This is -5.0% lower than average price of previous purchases of INVA. |
| GRFS - Grifols SA ADR | BUY | 1,015 @ USD 9.16 | USD 9,297 | The ETF bought 1015 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.16 compared to the previous average buy price of 9.43031. This is -2.9% lower than average price of previous purchases of GRFS. |
| COLL - Collegium Pharmaceutical Inc | BUY | 260 @ USD 35.65 | USD 9,269 | The ETF bought 260 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 35.65 compared to the previous average buy price of 31.1525. This is 14.4% higher than average price of previous purchases of COLL. |
| MNMD - Mind Medicine Inc | BUY | 645 @ USD 13.39 | USD 8,637 | The ETF bought 645 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 13.39 compared to the previous average buy price of 8.28468. This is 61.6% higher than average price of previous purchases of MNMD. |
| NRIX - Nurix Therapeutics Inc | BUY | 670 @ USD 12.78 | USD 8,563 | The ETF bought 670 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 12.78 compared to the previous average buy price of 12.0179. This is 6.3% higher than average price of previous purchases of NRIX. |
| ANAB - AnaptysBio Inc | BUY | 230 @ USD 36.47 | USD 8,388 | The ETF bought 230 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 36.47 compared to the previous average buy price of 23.2766. This is 56.7% higher than average price of previous purchases of ANAB. |
| XNCR - Xencor Inc | BUY | 590 @ USD 14.13 | USD 8,337 | The ETF bought 590 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 14.13 compared to the previous average buy price of 11.0209. This is 28.2% higher than average price of previous purchases of XNCR. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 600 @ USD 13.31 | USD 7,986 | The ETF bought 600 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 13.31 compared to the previous average buy price of 8.65434. This is 53.8% higher than average price of previous purchases of PHAT. |
| URGN - UroGen Pharma Ltd | BUY | 400 @ USD 19.85 | USD 7,940 | The ETF bought 400 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 19.85 compared to the previous average buy price of 14.282. This is 39.0% higher than average price of previous purchases of URGN. |
| ABUS - Arbutus Biopharma Corp | BUY | 1,630 @ USD 4.84 | USD 7,889 | The ETF bought 1630 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.84 compared to the previous average buy price of 3.56598. This is 35.7% higher than average price of previous purchases of ABUS. |
| KURA - Kura Oncology Inc | BUY | 755 @ USD 10.44 | USD 7,882 | The ETF bought 755 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 10.44 compared to the previous average buy price of 7.08168. This is 47.4% higher than average price of previous purchases of KURA. |
| PCRX - Pacira BioSciences, Inc. | BUY | 370 @ USD 21.27 | USD 7,870 | The ETF bought 370 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 21.27 compared to the previous average buy price of 23.9667. This is -11.3% lower than average price of previous purchases of PCRX. |
| FTRE - Fortrea Holdings Inc. | BUY | 755 @ USD 10.03 | USD 7,573 | The ETF bought 755 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 10.03 compared to the previous average buy price of 6.42836. This is 56.0% higher than average price of previous purchases of FTRE. |
| TNGX - Tango Therapeutics Inc | BUY | 925 @ USD 7.97 | USD 7,372 | The ETF bought 925 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 7.97 compared to the previous average buy price of 5.99472. This is 33.0% higher than average price of previous purchases of TNGX. |
| SPRY - Silverback Therapeutics Inc | BUY | 815 @ USD 8.62 | USD 7,025 | The ETF bought 815 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 8.62 compared to the previous average buy price of 13.99. This is -38.4% lower than average price of previous purchases of SPRY. |
| EYPT - Eyepoint Pharmaceuticals Inc | BUY | 575 @ USD 12.21 | USD 7,021 | The ETF bought 575 new shares of EYPT (Eyepoint Pharmaceuticals Inc). The shares were bought for an average price of 12.21 compared to the previous average buy price of 8.5502. This is 42.8% higher than average price of previous purchases of EYPT. |
| PAHC - Phibro Animal Health Corporation | BUY | 165 @ USD 41.86 | USD 6,907 | The ETF bought 165 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 41.86 compared to the previous average buy price of 27.744. This is 50.9% higher than average price of previous purchases of PAHC. |
| VIR - Vir Biotechnology Inc | BUY | 1,150 @ USD 5.93 | USD 6,820 | The ETF bought 1150 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 5.93 compared to the previous average buy price of 5.85152. This is 1.3% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 1,150 @ USD 5.93 | USD 6,820 | The ETF bought 1150 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 5.93 compared to the previous average buy price of 5.85152. This is 1.3% higher than average price of previous purchases of VIR. |
| REPL - Replimune Group Inc | BUY | 665 @ USD 10.25 | USD 6,816 | The ETF bought 665 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 10.25 compared to the previous average buy price of 8.89368. This is 15.3% higher than average price of previous purchases of REPL. |
| GERN - Geron Corporation | BUY | 5,280 @ USD 1.24 | USD 6,547 | The ETF bought 5280 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.24 compared to the previous average buy price of 1.5426. This is -19.6% lower than average price of previous purchases of GERN. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 1,460 @ USD 4.35 | USD 6,351 | The ETF bought 1460 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 4.35 compared to the previous average buy price of 3.95641. This is 9.9% higher than average price of previous purchases of PRME. |
| ERAS - Erasca Inc | BUY | 2,540 @ USD 2.46 | USD 6,248 | The ETF bought 2540 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 2.46 compared to the previous average buy price of 1.59838. This is 53.9% higher than average price of previous purchases of ERAS. |
| SVRA - Savara Inc | BUY | 1,440 @ USD 4.3 | USD 6,192 | The ETF bought 1440 new shares of SVRA (Savara Inc). The shares were bought for an average price of 4.3 compared to the previous average buy price of 2.68175. This is 60.3% higher than average price of previous purchases of SVRA. |
| TBPH - Theravance Biopharma Inc | BUY | 420 @ USD 14.3 | USD 6,006 | The ETF bought 420 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 14.3 compared to the previous average buy price of 11.5054. This is 24.3% higher than average price of previous purchases of TBPH. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 850 @ USD 7.03999 | USD 5,984 | The ETF bought 850 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 7.03999 compared to the previous average buy price of 7.39674. This is -4.8% lower than average price of previous purchases of DAWN. |
| ARVN - Arvinas Inc | BUY | 600 @ USD 9.93001 | USD 5,958 | The ETF bought 600 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 9.93001 compared to the previous average buy price of 8.67901. This is 14.4% higher than average price of previous purchases of ARVN. |
| TERN - Tern Plc | BUY | 730 @ USD 8.16 | USD 5,957 | The ETF bought 730 new shares of TERN (Tern Plc). The shares were bought for an average price of 8.16 compared to the previous average buy price of 5.0406. This is 61.9% higher than average price of previous purchases of TERN. |
| MGTX - MeiraGTx Holdings PLC | BUY | 670 @ USD 8.73 | USD 5,849 | The ETF bought 670 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 8.73 compared to the previous average buy price of 7.10512. This is 22.9% higher than average price of previous purchases of MGTX. |
| CSTL - Castle Biosciences Inc | BUY | 240 @ USD 24.21 | USD 5,810 | The ETF bought 240 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 24.21 compared to the previous average buy price of 21.2315. This is 14.0% higher than average price of previous purchases of CSTL. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 2,970 @ USD 1.95 | USD 5,792 | The ETF bought 2970 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 1.95 compared to the previous average buy price of 2.45589. This is -20.6% lower than average price of previous purchases of IOVA. |
| AVXL - Anavex Life Sciences Corp | BUY | 720 @ USD 8.02999 | USD 5,782 | The ETF bought 720 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 8.02999 compared to the previous average buy price of 9.63567. This is -16.7% lower than average price of previous purchases of AVXL. |
| RGNX - Regenxbio Inc | BUY | 440 @ USD 12.82 | USD 5,641 | The ETF bought 440 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 12.82 compared to the previous average buy price of 8.9789. This is 42.8% higher than average price of previous purchases of RGNX. |
| PACB - Pacific Biosciences of California | BUY | 2,660 @ USD 1.94 | USD 5,160 | The ETF bought 2660 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 1.94 compared to the previous average buy price of 1.53071. This is 26.7% higher than average price of previous purchases of PACB. |
| KROS - Keros Therapeutics Inc | BUY | 335 @ USD 15.03 | USD 5,035 | The ETF bought 335 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 15.03 compared to the previous average buy price of 13.5721. This is 10.7% higher than average price of previous purchases of KROS. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 565 @ USD 8.78 | USD 4,961 | The ETF bought 565 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 8.78 compared to the previous average buy price of 5.38071. This is 63.2% higher than average price of previous purchases of OLMA. |
| SIGA - SIGA Technologies Inc | BUY | 590 @ USD 8.30999 | USD 4,903 | The ETF bought 590 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 8.30999 compared to the previous average buy price of 6.75965. This is 22.9% higher than average price of previous purchases of SIGA. |
| PRTA - Prothena Corporation plc | BUY | 460 @ USD 10.48 | USD 4,821 | The ETF bought 460 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 10.48 compared to the previous average buy price of 8.95385. This is 17.0% higher than average price of previous purchases of PRTA. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 420 @ USD 11.32 | USD 4,754 | The ETF bought 420 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 11.32 compared to the previous average buy price of 5.88091. This is 92.5% higher than average price of previous purchases of FDMT. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 410 @ USD 10.97 | USD 4,498 | The ETF bought 410 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 10.97 compared to the previous average buy price of 12.3139. This is -10.9% lower than average price of previous purchases of KALV. |
| LXRX - Lexicon Pharmaceuticals Inc | BUY | 3,190 @ USD 1.34 | USD 4,275 | The ETF bought 3190 new shares of LXRX (Lexicon Pharmaceuticals Inc). The shares were bought for an average price of 1.34 compared to the previous average buy price of 1.01992. This is 31.4% higher than average price of previous purchases of LXRX. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 1,320 @ USD 3.14 | USD 4,145 | The ETF bought 1320 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.14 compared to the previous average buy price of 2.67579. This is 17.3% higher than average price of previous purchases of MRVI. |
| EOLS - Evolus Inc | BUY | 590 @ USD 6.72001 | USD 3,965 | The ETF bought 590 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 6.72001 compared to the previous average buy price of 9.3629. This is -28.2% lower than average price of previous purchases of EOLS. |
| GLPG - Galapagos NV ADR | BUY | 125 @ USD 31.34 | USD 3,918 | The ETF bought 125 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 31.34 compared to the previous average buy price of 28.893. This is 8.5% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 125 @ USD 31.34 | USD 3,918 | The ETF bought 125 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 31.34 compared to the previous average buy price of 28.893. This is 8.5% higher than average price of previous purchases of GLPG. |
| CGEM - Cullinan Oncology LLC | BUY | 515 @ USD 7.56001 | USD 3,893 | The ETF bought 515 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 7.56001 compared to the previous average buy price of 7.88159. This is -4.1% lower than average price of previous purchases of CGEM. |
| HCM - HUTCHMED China Ltd | BUY | 265 @ USD 14.43 | USD 3,824 | The ETF bought 265 new shares of HCM (HUTCHMED China Ltd). The shares were bought for an average price of 14.43 compared to the previous average buy price of 15.4726. This is -6.7% lower than average price of previous purchases of HCM. |
| HCM - Hitachi Construction Machinery Co. Ltd | BUY | 265 @ USD 14.43 | USD 3,824 | The ETF bought 265 new shares of HCM (Hitachi Construction Machinery Co. Ltd). The shares were bought for an average price of 14.43 compared to the previous average buy price of 15.4726. This is -6.7% lower than average price of previous purchases of HCM. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 400 @ USD 8.75999 | USD 3,504 | The ETF bought 400 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 8.75999 compared to the previous average buy price of 8.62241. This is 1.6% higher than average price of previous purchases of BCYC. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 905 @ USD 3.7 | USD 3,349 | The ETF bought 905 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.7 compared to the previous average buy price of 5.28371. This is -30.0% lower than average price of previous purchases of RCKT. |
| ALT - Altitude Group Plc | BUY | 725 @ USD 4.07001 | USD 2,951 | The ETF bought 725 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 4.07001 compared to the previous average buy price of 5.33084. This is -23.7% lower than average price of previous purchases of ALT. |
| ACIU - AC Immune Ltd | BUY | 850 @ USD 3.38001 | USD 2,873 | The ETF bought 850 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.38001 compared to the previous average buy price of 2.31844. This is 45.8% higher than average price of previous purchases of ACIU. |
| AUTL - Autolus Therapeutics Ltd | BUY | 1,860 @ USD 1.51 | USD 2,809 | The ETF bought 1860 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.51 compared to the previous average buy price of 1.86142. This is -18.9% lower than average price of previous purchases of AUTL. |
| LYEL - Lyell Immunopharma Inc | BUY | 160 @ USD 16.53 | USD 2,645 | The ETF bought 160 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 16.53 compared to the previous average buy price of 3.66588. This is 350.9% higher than average price of previous purchases of LYEL. |
| EDIT - Editas Medicine Inc | BUY | 820 @ USD 3.01001 | USD 2,468 | The ETF bought 820 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 3.01001 compared to the previous average buy price of 2.73618. This is 10.0% higher than average price of previous purchases of EDIT. |
| TRDA - Entrada Therapeutics Inc | BUY | 350 @ USD 6.9 | USD 2,415 | The ETF bought 350 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 6.9 compared to the previous average buy price of 7.69236. This is -10.3% lower than average price of previous purchases of TRDA. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 245 @ USD 9.63002 | USD 2,359 | The ETF bought 245 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 9.63002 compared to the previous average buy price of 15.0932. This is -36.2% lower than average price of previous purchases of ARCT. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 720 @ USD 3.26999 | USD 2,354 | The ETF bought 720 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.26999 compared to the previous average buy price of 3.33204. This is -1.9% lower than average price of previous purchases of AVIR. |
| ALLO - Allogene Therapeutics Inc | BUY | 1,890 @ USD 1.21 | USD 2,287 | The ETF bought 1890 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.21 compared to the previous average buy price of 1.34631. This is -10.1% lower than average price of previous purchases of ALLO. |
| HUMA - Humacyte Inc | BUY | 1,400 @ USD 1.62 | USD 2,268 | The ETF bought 1400 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.62 compared to the previous average buy price of 2.25575. This is -28.2% lower than average price of previous purchases of HUMA. |
| VYGR - Voyager Therapeutics Inc | BUY | 445 @ USD 4.51999 | USD 2,011 | The ETF bought 445 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4.51999 compared to the previous average buy price of 3.81781. This is 18.4% higher than average price of previous purchases of VYGR. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 1,320 @ USD 1.50001 | USD 1,980 | The ETF bought 1320 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 1.50001 compared to the previous average buy price of 1.10135. This is 36.2% higher than average price of previous purchases of IRWD. |
| OABI - OmniAb Inc. | BUY | 1,065 @ USD 1.49 | USD 1,587 | The ETF bought 1065 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.49 compared to the previous average buy price of 1.9486. This is -23.5% lower than average price of previous purchases of OABI. |
| ALEC - Alector Inc | BUY | 915 @ USD 1.52 | USD 1,391 | The ETF bought 915 new shares of ALEC (Alector Inc). The shares were bought for an average price of 1.52 compared to the previous average buy price of 1.99027. This is -23.6% lower than average price of previous purchases of ALEC. |
| MXCT - MaxCyte Inc | BUY | 920 @ USD 1.51001 | USD 1,389 | The ETF bought 920 new shares of MXCT (MaxCyte Inc). The shares were bought for an average price of 1.51001 compared to the previous average buy price of 2.24162. This is -32.6% lower than average price of previous purchases of MXCT. |
| FATE - Fate Therapeutics Inc | BUY | 935 @ USD 1.29 | USD 1,206 | The ETF bought 935 new shares of FATE (Fate Therapeutics Inc). The shares were bought for an average price of 1.29 compared to the previous average buy price of 1.19269. This is 8.2% higher than average price of previous purchases of FATE. |
| MGNX - MacroGenics Inc | BUY | 535 @ USD 1.595 | USD 853 | The ETF bought 535 new shares of MGNX (MacroGenics Inc). The shares were bought for an average price of 1.595 compared to the previous average buy price of 1.58427. This is 0.7% higher than average price of previous purchases of MGNX. |
| PLRX - Pliant Therapeutics Inc | BUY | 500 @ USD 1.63999 | USD 820 | The ETF bought 500 new shares of PLRX (Pliant Therapeutics Inc). The shares were bought for an average price of 1.63999 compared to the previous average buy price of 1.4883. This is 10.2% higher than average price of previous purchases of PLRX. |
| BMEA - Biomea Fusion Inc | BUY | 595 @ USD 1.32999 | USD 791 | The ETF bought 595 new shares of BMEA (Biomea Fusion Inc). The shares were bought for an average price of 1.32999 compared to the previous average buy price of 1.87958. This is -29.2% lower than average price of previous purchases of BMEA. |
| STRO - Sutro Biopharma | BUY | 680 @ USD 1.16 | USD 789 | The ETF bought 680 new shares of STRO (Sutro Biopharma). The shares were bought for an average price of 1.16 compared to the previous average buy price of 0.891639. This is 30.1% higher than average price of previous purchases of STRO. |
| MRSN - Mersana Therapeutics Inc | BUY | 40 @ USD 9.29987 | USD 372 | The ETF bought 40 new shares of MRSN (Mersana Therapeutics Inc). The shares were bought for an average price of 9.29987 compared to the previous average buy price of 0.491668. This is 1,791.5% higher than average price of previous purchases of MRSN. |
| OKUR - OKUR | BUY | 105 @ USD 3.34995 | USD 352 | The ETF bought 105 new shares of OKUR (OKUR). The shares were bought for an average price of 3.34995 compared to the previous average buy price of 6.25199. This is -46.4% lower than average price of previous purchases of OKUR. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| APLS - Apellis Pharmaceuticals Inc | HOLD | 0 @ USD 20.73 | USD 0 | The current share valuation price of APLS based on adjusted close was USD 20.73. The average price that APLS shares were previous bought at was USD 21.112. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in APLS has fallen by USD 752,460 compared to the previous valuation of Apellis Pharmaceuticals Inc |
| GH - Guardant Health Inc | HOLD | 0 @ USD 92.41 | USD 0 | The current share valuation price of GH based on adjusted close was USD 92.41. The average price that GH shares were previous bought at was USD 52.4554. The current market price is 76.2% higher than average price they were purchased at. The value of the holding in GH has increased by USD 1,601,070 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-10-30 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-10-30 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 4.32001 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 4.32001. The average price that VNDA shares were previous bought at was USD 4.8799. The current market price is -11.5% lower than average price they were purchased at. The value of the holding in VNDA has fallen by USD 43,878 compared to the previous valuation of Vanda Pharmaceuticals Inc |